Jonathan McNeill, Chief Business Officer at Dyne Therapeutics, Inc. (DYN), sold 51,346 shares at $27.50 ($1.5M) on 2024-02-29, disclosed to the SEC on 2024-03-01.
Scheduled sale ($1.5M) by Chief Business Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $27.50 | 4,268 | $117K | 8.0% |
| 2 | $28.25 | 14,103 | $398K | 27.2% |
| 3 | $28.25 | 14,103 | $398K | 27.2% |
| 4 | $29.06 | 8,715 | $253K | 17.3% |
| 5 | $29.06 | 8,715 | $253K | 17.3% |
| 6 | $29.70 | 1,442 |
| $43K |
| 2.9% |
| Total | $28.50 avg | 51,346 | $1.5M | 100% |
| Filing → |
| DYN | SELL | 2024-08-20 | $122K | — | Filing → |
| DYN | SELL | 2024-06-11 | $114K | — | Filing → |
| DYN | SELL | 2024-05-17 | $143K | — | Filing → |